TY  - JOUR
T1  - GLP-1 Receptor Agonist Cardiovascular Protection among Type-2 Diabetes Patients: A Literature Review
A1  - Khaled Mesfer S Alghamdi
A1  - Bakr Abdullah M Alqahtani
A1  - Abdullah Hussain O Alhazmi
A1  - Zeyad Adel A Alsaedi
A1  - Waleed Talal M Alsulaimani
A1  - Faisal Besheit H Almatrafi
A1  - Abdulrahman Mohammed A Alhumaid
A1  - Muhannad Ahmed Alzahrani
A1  - Anas Abdullah G Al Alyany
A1  - Saeed Oudah S Alasiri
A1  - Nahd Hasan Alesawy
A1  - Shorouq Abdualaziz Alshammar
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2021
VL  - 12
IS  - 5
DO  - 10.51847/ChNOtMbUUT
SP  - 76
EP  - 80
N2  - T2DM (Type 2 Diabetes Mellitus) remains a main global health issue, particularly if cardiovascular complications started to evolve. Type 2 diabetes is the main cause of renal and cardiovascular adverse consequences. Adequate management of T2DM depends on glycemic control and prevent cardiovascular or renal complications. Hence, certain antidiabetic agents have provided cardiovascular protection, of which one of them is the glucose-like peptide 1 receptor agonists. The present literature review aims to assess the cardiovascular efficiency and safety of glucose-like peptide 1 receptor agonists in patients with T2DM. We used the PubMed database, searching for relevant articles to the title. We used the following Mesh words: heart failure, GLP-1 receptor agonist, type 2 diabetes mellitus, cardiovascular consequences. GLP-1 receptor agonists are effective antidiabetic agents in regards to the glycemic control and safety profile for cardiovascular disease. GLP-1 receptor agonists seem to have promising cardiovascular protection in cardiovascular and all-cause mortality, including fatal and non-fatal myocardial infarction, fatal and non-fatal stroke. However, the increased risk of heart failure hospitalization remains debatable, and further clinical trials are recommended to evaluate this concern. A common side effect is related to gastrointestinal upset, and overall, it is transient and generally does not require discontinuation of the treatment.
UR  - https://pharmacophorejournal.com/article/glp-1-receptor-agonist-cardiovascular-protection-among-type-2-diabetes-patients-a-literature-review-58iiayvwzaebiln
ER  -